Tarsus Pharmaceuticals, Inc. (TARS): Results of Operations and Financial Condition
Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 milli
How this was made
The 30-second read
Why it matters
The newest tradable inputs are the raised full-year XDEMVY net product sales guidance range, the $125M private placement financing, and the signed acquisition agreement to expand the retina pipeline with a Phase 3 Stargardt program (ALK-001).
Market read
Traders can reprice TARS on the combination of a guidance raise, a signed M&A expansion into retina, and disclosed financing terms.
What to watch
The filing highlights multiple 2027-2028 topline catalysts (KORE, Calliope, COMFORT) but does not provide probability-weighted outcomes; execution risk remains the key swing factor.
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
XDEMVY net product sales reached $173.9 million, more than 69% above the prior-year period, while the company increased full-year 2026 XDEMVY net product sales guidance to $685-705 million. The net loss narrowed to $18.6 million despite higher commercial, DTC, patient-support, R&D, and corporate spending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| XDEMVY net product salesother | $173.9 million | – | more than 69% |
| Cost of salesother | $12.1 million | – | – |
| Gross marginsother | 93% | – | – |
| Research and development expensesother | $31.0 million | – | – |
| R&D non-cash stock-based compensation expenseother | $3.0 million | – | – |
| Selling, general and administrative expensesother | $150.7 million | – | – |
| SG&A non-cash stock-based compensation expenseother | $10.1 million | – | – |
| Net lossother | $18.6 million | – | – |
| Basic and diluted net loss per shareother | $(0.43) | – | – |
| Cash, cash equivalents and marketable securitiesother | $449.7 million | – | – |
| Year-to-date product salesother | $319.3 million | – | – |
| Year-to-date license fees and collaboration revenueother | $16.7 million | – | – |
| Year-to-date cost of salesother | $21.5 million | – | – |
| Year-to-date gross marginsother | 93% | – | – |
| Year-to-date research and development expensesother | $53.4 million | – | – |
| Year-to-date R&D non-cash stock compensation expenseother | $6.0 million | – | – |
| Year-to-date selling, general and administrative expensesother | $287.1 million | – | – |
| Year-to-date SG&A non-cash stock compensation expenseother | $18.8 million | – | – |
| Year-to-date net lossother | $25.5 million | – | – |
| Year-to-date basic and diluted net loss per shareother | $(0.59) | – | – |
full-year 2026 outlook
- RevenueXDEMVY net product sales of $685-705 million
What drove it
- Product sales growth was driven by higher volume and improvements in the gross-to-net discount.
- The number of eye care professionals prescribing XDEMVY five or more times per week has doubled year-over-year.
- Direct-to-consumer initiatives continued to contribute to prescription growth and awareness.
- XDEMVY.com website engagement increased by more than 30% since the start of both new initiatives, with high-value actions up 19%.
- Unaided awareness of Demodex blepharitis was approximately 30% versus 2% of patients surveyed at the beginning of the Company’s DTC campaign.
- Year-to-date license fees and collaboration revenue included a $15.0 million regulatory milestone under the China out-license and $1.7 million of required China withholding tax associated with this milestone.
Concerns
- Second-quarter SG&A expenses were $150.7 million, compared to $103.0 million for the same period in 2025, reflecting commercial and marketing costs including DTC advertising, patient support, information technology, legal, professional services, and personnel additions.
- Second-quarter R&D expenses were $31.0 million, compared to $15.6 million for the same period in 2025, including $8.0 million of TP-05 program expenses related to the Calliope trial.
- The company reported a second-quarter net loss of $18.6 million.
- The acquisition of Alkeus Pharmaceuticals remains subject to the announced agreement, while the filing identifies ALK-001 as an investigational therapy with a Phase 3 clinical program.
What to watch
- Topline data from the Phase 2 KORE trial of TP-04 is expected in the first half of 2027.
- Topline data from the Phase 2 Calliope trial of TP-05 is expected in the first half of 2027, with the potential to support a Phase 3-ready package.
- The company anticipates initiating the Phase 3 COMFORT trial of IRX-101 in the first half of 2027, with topline results expected in 2028.
- Execution against full-year 2026 XDEMVY net product sales guidance of $685-705 million.
- Progress of the announced acquisition of Alkeus Pharmaceuticals and its ALK-001 Phase 3 program for Stargardt disease.
Balance sheet and cash flow
- As of June 30, 2026, cash, cash equivalents and marketable securities were $449.7 million.
- Priced $125 million private placement financing which included participation from top-tier funds and several existing Alkeus Pharmaceuticals investors.
Analysis
Tarsus reported a record commercial quarter for XDEMVY, with net product sales of $173.9 million versus $102.7 million in the same period in 2025. Management attributed the increase to higher volume and improvements in the gross-to-net discount. Adoption indicators also remained favorable: the number of eye care professionals prescribing XDEMVY five or more times per week doubled year-over-year, while direct-to-consumer initiatives contributed to prescription growth and awareness.
Product economics remained high margin, with gross margins of 93% compared with 94% in the same period in 2025. Cost of sales was $12.1 million, compared with $6.2 million, reflecting XDEMVY manufacturing costs, royalties on net product sales, and amortization of milestone payments to the company’s licensor. The filing raised full-year 2026 XDEMVY net product sales guidance to $685-705 million.
Commercial investment rose materially. SG&A expenses were $150.7 million compared with $103.0 million, driven principally by $21.2 million of commercial and marketing costs including DTC advertising, $19.5 million of patient-support, information-technology, legal, and professional-services costs, and $6.7 million of payroll and personnel-related costs. R&D expenses increased to $31.0 million from $15.6 million, including $8.0 million of TP-05 program expenses and $3.1 million of TP-03 program expenses. Despite these investments, net loss narrowed to $18.6 million from $20.3 million, and basic and diluted net loss per share improved to $(0.43) from $(0.48).
For the first six months of 2026, product sales were $319.3 million compared with $181.0 million in the same period in 2025. The company also reported $16.7 million of license fees and collaboration revenue from its China out-license partner, including a $15.0 million regulatory milestone and $1.7 million of required China withholding tax recorded on a gross basis. Year-to-date net loss narrowed to $25.5 million from $45.5 million, while year-to-date SG&A increased to $287.1 million and R&D increased to $53.4 million.
Tarsus ended June 30, 2026 with $449.7 million of cash, cash equivalents and marketable securities and announced a $125 million private placement financing. Strategically, the company completed the iRenix Medical acquisition, is advancing TP-04, TP-05, and IRX-101, and entered into an agreement to acquire Alkeus Pharmaceuticals and ALK-001. The next disclosed clinical milestones are TP-04 and TP-05 topline data in the first half of 2027, followed by anticipated IRX-101 Phase 3 initiation in the first half of 2027 and expected topline results in 2028.
Management, verbatim
XDEMVY delivered another record quarter, reflecting strong underlying demand and commercial execution.
Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
This performance gives us the commercial foundation and financial strength to remain intensely focused on growing XDEMVY while strategically investing in our next wave of growth.
Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
Not in the filing
stated, not guessed- Total revenue for the second quarter 2026 and the same period in 2025.
- Total revenue for the year-to-date 2026 period and the same period in 2025.
- Operating income or loss.
- Operating cash flow.
- Free cash flow.
- Debt balance.
- Share repurchases and dividends.
- Prior-quarter comparisons for reported metrics.
- Full-year 2026 gross margin, operating-expense, and tax-rate guidance.
- Prior outlook figures for comparison with actual results.
- Reported operating segments and segment revenue.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings release covering Q2 2026 results, updated full-year guidance, and an announced acquisition of Alkeus Pharmaceuticals.
Ticker impact
Tarsus reports Q2 2026 results with record XDEMVY sales and raises full-year 2026 net product sales guidance, plus announces an Alkeus acquisition.
Likely positive bias for TARS on guidance raise and acquisition headline, tempered by financing and integration/clinical execution risk.
The filing discloses specific Q2 sales growth, explicit full-year guidance range, and a priced $125M private placement alongside a signed acquisition agreement for Alkeus and its Phase 3 Stargardt program.
Market effects
Eye-care specialty pharma sentiment may improve as late-stage retina pipeline and commercial execution signals strengthen.
Limited direct regional spillover; primarily US small/mid-cap biotech sentiment.
China out-license milestone revenue is mentioned, but the disclosed catalyst is company-specific rather than a global sector shock.
Counterpoint
The guidance raise and deal may be offset by materially higher operating expenses (R&D and SG&A) and the $125M private placement, which can pressure near-term per-share metrics.
Key entities
- companyTarsus Pharmaceuticals, Inc.
NASDAQ-listed eye-care specialty pharma reporting Q2 2026 results, raised 2026 XDEMVY guidance, and announcing the Alkeus acquisition plus $125M private placement.
- companyAlkeus Pharmaceuticals
Target of Tarsus’ announced acquisition, bringing ALK-001 and a Phase 3 Stargardt disease program.
- productXDEMVY
Tarsus’ Demodex blepharitis therapy with record Q2 net product sales and raised full-year guidance.
